ABII: Summary for Abraxis Bioscience Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:22pm EST - Canadian Markets close in 1 hour and 38 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Abraxis BioScience, Inc. (ABII)

At 13:58 EST: 33.8375 USD

0.2075 (0.62%)

MORE ON ABII

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Abraxis Bioscience Inc. (NasdaqNM:ABII) Delayed quote data

Last Trade:	33.8375 USD
Trade Time:	1:58PM EST
Change:	0.2075 (0.62%)
Prev Close:	33.63
Open:	33.91
Bid:	33.66 x 200
Ask:	33.91 x 400
1y Target Est:	N/A

Day's Range:	33.45 - 34.27
52wk Range:	24.52 - 74.50
Volume:	7,776
Avg Vol (3m):	52,850
Market Cap:	1.36B
P/E (ttm):	N/A
EPS (ttm):	-6.634
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Free Annual Reports

Add ABII to Portfolio

Download Data

HEADLINES

•	Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
	Wall Street Transcript (Fri, Nov 20)

•	Healthcare Bill Will Be Law By New Year Says Morningstar Strategist
	Wall Street Transcript (Mon, Nov 9)

•	Morningstar Strategist Says Healthcare Bill Will Be Law By End Of Year: Is Your Portfolio Ready?
	Wall Street Transcript (Mon, Nov 9)

•	ABRAXIS BIOSCIENCE, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 9)

•	New Star Analyst Rankings for Abraxis Bioscience Inc.
	StarMine (Sun, Nov 8)

•	Abraxis opens expanded plant in Phoenix, expected to create 200 jobs
	at bizjournals.com (Thu, Nov 5)

•	Abraxis BioScience, Inc. Earnings Call scheduled for 11:30 am ET today
	CCBN (Thu, Nov 5)

•	Abraxis BioScience Reports 2009 Third Quarter Financial Results
	Business Wire (Thu, Nov 5)

•	ABRAXANE® Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma
	Business Wire (Thu, Nov 5)

•	Q3 2009 Abraxis BioScience, Inc. Earnings Release - Before Market Open
	CCBN (Thu, Nov 5)

More Headlines for ABII...

ANALYST

EPS Est (next year) (Dec-09) :	-3.10
EPS Est (in 2 years) (Dec-10) :	-2.13
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses.

Full Company Profile

Add to Portfolio

Email to a Friend

•